Early Intervention Services Best for Early-Phase Psychosis

Share this content:
Early Intervention Services Best for Early-Phase Psychosis
Early Intervention Services Best for Early-Phase Psychosis

MONDAY, May 7, 2018 (HealthDay News) -- Early intervention services (EIS) are better than treatment as usual (TAU) for early-phase psychosis across meta-analyzable outcomes, according to a review published online May 2 in JAMA Psychiatry.

Christoph U. Correll, M.D., from The Zucker Hillside Hospital in Glen Oaks, N.Y., and colleagues conducted a systematic literature review to compare EIS with TAU for early-phase psychosis. Data were included for 10 randomized clinical trials among 2,176 patients.

The researchers found that for all 13 meta-analyzable outcomes, EIS were correlated with better outcomes than TAU at the end of treatment. The outcomes included discontinuation of all-cause treatment (risk ratio, 0.7), at least one psychiatric hospitalization (risk ratio, 0.74), involvement in school or work (risk ratio, 1.13), total symptom severity (standardized mean difference [SMD], −0.32), and positive and negative symptom severity (SMD, −0.22 and −0.28, respectively). At six, nine to 12, and 18 to 24 months of treatment, the superiority of EIS regarding all outcomes was evident apart from general symptom and depressive symptom severity at 18 to 24 months.

"In early-phase psychosis, EIS are superior to TAU across all meta-analyzable outcomes," the authors write. "These results support the need for funding and use of EIS in patients with early-phase psychosis."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »